Prescription drug · NDA
Phyrago (Dasatinib) NDC 70709-151
Dasatinib 20 mg/1 · Tablet · Oral · Cycle Pharmaceuticals Ltd
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70709-151-20 | 7070901512070709015120 | 60 TABLET in 1 BOTTLE (70709-151-20)Marketed from Sep 22, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Phyrago
- Generic name (nonproprietary)
- dasatinib
- Active ingredients
- Dasatinib — 20 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Cycle Pharmaceuticals LtdNDC labeler code 70709
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 216099
- Marketing start
- Listing expires
- Other FDA classes
- Cytochrome P450 3A4 Inhibitors (Mechanism)Protein Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 70709-151_c853d4c8-8373-4603-bc62-41e53130c0aaSPL ID c853d4c8-8373-4603-bc62-41e53130c0aaSPL set ID 60976d1e-c415-417f-8168-4e07999a7281RxCUI 643105, 643107, 643109, 799047, 1045402, 1045406, 2691837, 2691839, 2691841, 2691843, 2691845, 2691847UNII RBZ1571X5H
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470709015120followed by a unit qualifier and the quantityPackage 70709-0151-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1. INDICATIONS AND USAGE PHYRAGO is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. PHYRAGO is indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. PHYRAGO TM is a kinase inhibitor indicated for the treatment of newly diagnosed a…
Excerpt only. Read the full label for complete information.
About NDC 70709-151
- What is NDC 70709-151?
- 70709-151 is the product NDC for Phyrago (dasatinib), Dasatinib 20 mg/1 tablet, listed with the FDA by Cycle Pharmaceuticals Ltd. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Phyrago (Dasatinib).
- What is the active ingredient?
- Dasatinib.
- Who is the labeler?
- Cycle Pharmaceuticals Ltd, NDC labeler code 70709. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Phyrago?
- 5 other product NDCs are listed under this name. See all Phyrago NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Phyrago products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Phyragodasatinib | Dasatinib 50 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-152 | 70709-0152-50 |
| Phyragodasatinib | Dasatinib 70 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-153 | 70709-0153-70 |
| Phyragodasatinib | Dasatinib 80 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-154 | 70709-0154-80 |
| Phyragodasatinib | Dasatinib 100 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-155 | 70709-0155-10 |
| Phyragodasatinib | Dasatinib 140 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-156 | 70709-0156-14 |
Other NDCs under NDA 216099
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Phyragodasatinib | Dasatinib 50 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-152 |
| Phyragodasatinib | Dasatinib 70 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-153 |
| Phyragodasatinib | Dasatinib 80 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-154 |
| Phyragodasatinib | Dasatinib 100 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-155 |
| Phyragodasatinib | Dasatinib 140 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-156 |